Some targeted therapy drugs that are directed at (target) proteins to prevent, treat and reduce the risk of breast cancer recurrence are monoclonal antibody like Trastuzumab (Herceptin). Trastuzumab is an antibody drug that specially target HER2-positive cancer cells. Trastuzumab attaches to the HER2 protein on the surface of HER2-positive breast cancer cells and slow/stop their growth.
Isolation of a monoclonal antibody named with high specificity towards HER
Trastuzumab approved in US for treatment of HER2 positive breast cancer
Trastuzumab approved in Europe
Trastuzumab approved for treatment in adjuvant of HER2 node positive breast cancer
Lapatinib approved for HER2 breast cancer
Trastuzumab emtansine was approved in USA breast cancer
Trastuzumab biosimilar Hertraz (MYL-14010) was approved in India and the trastuzumab biosimilar CT-P6 was approved in Korea
Trastuzumab was added to the South African Essential Medicines List (EML) in 2017 for the adjuvant management of HER2-positive early breast cancer.
Biosimilar agents currently approved in the European Union, the United States, and Canada Enoxaparin sodium (2017), Bevacizumab & Adalimumab (2017), Herzuma (2018), Ontruzant/ Trazimera/ Kanjinti (2019)
FDA approved a fixed-dose combination of pertuzumab (Perjeta) and trastuzumab (Herceptin)
Enhertu approved in USA
Top patented combination of trastuzumab
Biosimilar of Trastuzumab
Trastuzumab Deruxtecan trials have introduced a new subtype of HER2 expressing metastatic breast cancer. Targeting and treating HER2-low breast cancer HER 2 low breast cancer, which represent at least 50% of breast cancer have raised new challenges. Unfortunately, the low HER2 expression failed to provide clinical prognosis benefits. The available HER2-targeted therapies are inefficient in HER2-low BC, and treatment options are restricted after the initial treatment progression. Despite the ineffectiveness of trastuzumab for HER2-low BC, the ability of ADCs to significantly improve prognosis has spurred interest in conventional targeted agents